Skip to main content

Call For Papers

Infections in Immunocompromised Hosts

This special issue of the Annals of Clinical Microbiology and Antimicrobials will focus on infections in immunocompromised populations, and we welcome submissions relating to clinical presentations, antimicrobial therapy, epidemiology, pathogen diagnostics and host immunology including host-pathogen interaction. 

Guest  Editor - Dr David Lowe (University College London)

Articles

Aims and scope

Annals of Clinical Microbiology and Antimicrobials considers good quality, novel and international articles of more than regional relevance; the journal covers the clinical microbiology of bacteria, viruses and fungi, as well as antimicrobial treatment of infectious diseases in clinical settings.

Research articles must include epidemiological and/or clinical information about isolates; we also welcome systemic reviews, and clinical case reports of high international significance.

We often invite reviews focussing on important current issues, and we also welcome submission of formal systematic reviews. Authors who are considering submit an unsolicited review should contact the editorial office for advice on the relevance of the content and the quality of evidence that is expected.

Highlighted Associate Editor: Satoshi Nishida

Satoshi NishidaMy research started to focus on the molecular mechanism of bacterial DNA replication in my Ph.D. study at Kyushu University (1999). As a postdoc (1999-2002), I focused on host-microbe interaction in humans, especially Aspergillus fumigatus, at National Center for Child Health and Development, Tokyo, Japan. Next, I worked at the University of Tokyo on a target discovery for novel antimicrobial drug development in collaboration with Shionogi, Co (2002-2005). Peptidoglycan is a structure specific to bacteria, and a drug that explicitly inhibits its biosynthetic pathway has few side effects. I performed an analysis on peptidoglycan synthases essential for growth as a research associate at Musashino University (2005-2007). I was trained in analyzing drug resistance and virulence gene expression and antibiotic response at the University of Chicago and Harvard University as a research associate and associate, respectively (2007-2012). Next, I joined as a chief scientist in Genome Pharmaceuticals Institute Co., a biotech venture at the University of Tokyo, and used an insect infection model and developed new probiotics (2013-2015).


In 2015, I moved to Teikyo University School of Medicine, and my research has shifted to analyzing multidrug-resistant bacteria because of its critical emergence in community and clinical settings. Collaborating with clinical colleagues, we have identified multidrug-resistant nosocomial pathogens from patients. In addition, we evaluated the use of probiotics as a non-antibiotic experimental therapy in an insect infection model. Now, we are integrating whole-genome sequencing and an experimental infection model to explore infection and colonization of multidrug-resistant nosocomial pathogens in human health and disease with curative intent.

Editor profiles

Hakan Leblebicioglu, Editor-in-Chief

Professor Leblebicioglu is the former head of the Department of Infectious Diseases and Clinical Microbiology at Ondokuz Mayis University Medical School in Turkey and working at Samsun Liv Hospital, Turkey. He is currently a Fellow of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), a founding member and Honorary Chief of ESCMID Study Group for Infections in Travelers and Migrants (ESGITM) and also a member of the Study Group for Viral Hepatitis (ESGVH). He has authored 162 publications in peer-reviewed international medical journals (H index is 31 in Web of Science), mainly in Crimean Congo hemorrhagic fever, viral hepatitis and healthcare associated infections. He has conducted workshops and courses in the area of effective communication, presentation skills, proposal and manuscript writing.

Tim McHugh, Editor-in-Chief

Professor McHugh leads the UCL Centre for Clinical Microbiology (CCM). Located at the Royal Free Hospital, CCM aims to improve the diagnosis and treatment of infectious diseases and contributes in the areas of antimicrobial resistance, infection in patients with immunosuppression and hospital acquired infection. Prof McHugh has a particular focus on respiratory infection and CCM has activities in all stages of the TB drug development pathway with projects on evaluation of new compounds as well as supporting the laboratory aspects of clinical trials. An underlying theme is the development of biomarkers of treatment outcome, whether transcriptomic analysis of in vitro treatments or the more complex picture of monitoring outcome in patients.

Annual Journal Metrics